Since, in the current study, depression is the disease state related to the greatest number of PGx gene–drug pairs having both FDA/CPIC categorizations, it is worth highlighting that CYP2C19 and CYP2D6 are primarily responsible for the metabolism of those antidepressant medications. Here, CYP2C19 is linked to depressive symptom measurement.